Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $20.00

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $20.00.

ANRO has been the topic of several research analyst reports. Robert W. Baird decreased their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus decreased their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Alto Neuroscience Trading Down 2.0 %

NYSE ANRO opened at $4.43 on Tuesday. Alto Neuroscience has a twelve month low of $3.56 and a twelve month high of $24.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The company’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $9.01.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.05. As a group, analysts predict that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in ANRO. Geode Capital Management LLC boosted its position in Alto Neuroscience by 148.7% during the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock valued at $5,378,000 after purchasing an additional 281,018 shares during the last quarter. State Street Corp grew its stake in shares of Alto Neuroscience by 123.7% in the third quarter. State Street Corp now owns 236,857 shares of the company’s stock valued at $2,710,000 after buying an additional 130,985 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Alto Neuroscience by 80.3% in the third quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock valued at $9,521,000 after buying an additional 370,612 shares in the last quarter. Franklin Resources Inc. increased its holdings in Alto Neuroscience by 95.3% during the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after buying an additional 595,673 shares during the last quarter. Finally, TD Asset Management Inc bought a new stake in Alto Neuroscience during the second quarter worth $928,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.